Abstract:In the race to combat ever-evolving diseases, the drug discovery process often faces the hurdles of high-cost and time-consuming procedures. To tackle these challenges and enhance the efficiency of identifying new therapeutic agents, we introduce VirtuDockDL, which is a streamlined Python-based web platform utilizing deep learning for drug discovery. This pipeline employs a Graph Neural Network to analyze and predict the effectiveness of various compounds as potential drug candidates. During the validation phase, VirtuDockDL was instrumental in identifying non-covalent inhibitors against the VP35 protein of the Marburg virus, a critical target given the virus’s high fatality rate and limited treatment options. Further, in benchmarking, VirtuDockDL achieved 99% accuracy, an F1 score of 0.992, and an AUC of 0.99 on the HER2 dataset, surpassing DeepChem (89% accuracy) and AutoDock Vina (82% accuracy). Compared to RosettaVS, MzDOCK, and PyRMD, VirtuDockDL outperformed them by combining both ligand- and structure-based screening with deep learning. While RosettaVS excels in accurate docking but lacks high-throughput screening, and PyRMD focuses on ligand-based methods without AI integration, VirtuDockDL offers superior predictive accuracy and full automation for large-scale datasets, making it ideal for comprehensive drug discovery workflows. These results underscore the tool’s capability to identify high-affinity inhibitors accurately across various targets, including the HER2 protein for cancer therapy, TEM-1 beta-lactamase for bacterial infections, and the CYP51 enzyme for fungal infections like Candidiasis. To sum up, VirtuDockDL combines user-friendly interface design with powerful computational capabilities to facilitate rapid, cost-effective drug discovery and development. The integration of AI in drug discovery could potentially transform the landscape of pharmaceutical research, providing faster responses to global health challenges. The VirtuDockDL is available at https://github.com/FatimaNoor74/VirtuDockDL .

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Development of Ligand-based Big Data Deep Neural Network Models for Virtual Screening of Large Compound Libraries.

Deep Learning Pipeline for Accelerating Virtual Screening in Drug Discovery

Deep Learning and Virtual Drug Screening

Deep Learning in Virtual Screening: Recent Applications and Developments

Kinome-Wide Virtual Screening by Multi-Task Deep Learning

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Validation of Deep Learning-Based DFCNN in Extremely Large-Scale Virtual Screening and Application in Trypsin I Protease Inhibitor Discovery

Artificial intelligence: Machine learning approach for screening large database and drug discovery

Novel Big Data-Driven Machine Learning Models for Drug Discovery Application

Deep Learning-Based Construction of a Drug-Like Compound Database and Its Application in Virtual Screening of HsDHODH Inhibitors

Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking

An artificial intelligence accelerated virtual screening platform for drug discovery

Exploration on Learning Molecular Docking with Deep Learning Models

DENVIS: Scalable and High-Throughput Virtual Screening Using Graph Neural Networks with Atomic and Surface Protein Pocket Features

Virtual Screening of Molecules via Neural Fingerprint-based Deep Learning Technique

Ultra‐Large Virtual Screening: Definition, Recent Advances, and Challenges in Drug Design

Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery

Docking Score ML: Target-Specific Machine Learning Models Improving Docking-Based Virtual Screening in 155 Targets

Advances in machine intelligence-driven virtual screening approaches for big-data